Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity. We evaluated a novel, fully automated ex vivo DSS platform that us...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Spinner, Michael A., Aleshin, Alexey, Santaguida, Marianne T., Schaffert, Steven A., Zehnder, James L., Patterson, A. Scott, Gekas, Christos, Heiser, Diane, Greenberg, Peter L.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Myeloid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322964/
https://ncbi.nlm.nih.gov/pubmed/32569379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001934
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares